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Abstract
There is convincing epidemiological and clinical evidence that, independent of aging, lifestyle and, notably, nutrition
are associated with development or progression of major human cancers, including breast, prostate, colorectal tumors,
and an increasingly large collection of diet-related cancers. Mechanisms underlying this association are mostly related
to the distinct epigenetic effects of different dietary patterns. In this context, Mediterranean diet has been reported to
significantly reduce mortality rates for various chronic illnesses, including cardiovascular diseases, neurodegenerative
diseases and cancer. Although many observational studies have supported this evidence, dietary intervention studies
using a Mediterranean dietary pattern or its selected food components are still limited and affected by a rather large
variability in characteristics of study subjects, type and length of intervention, selected end-points and statistical
analysis. Here we review data of two of our intervention studies, the MeDiet study and the DiMeSa project, aimed at
assessing the effects of traditional Mediterranean diet and/or its component(s) on a large panel of both plasma and
urine biomarkers. Both published and unpublished results are presented and discussed.
Background
Cancer represents today the second leading cause of
death worldwide after cardiovascular diseases, despite
the fact that cancer mortality rates have been declin-
ing since 90ies because of either early diagnosis/
screening programs or an increasingly larger array of
therapeutic options [1].
In this context, the continuous rise in life expectancy
has significantly contributed to the steady increase of
cancer risk among general population [2]. However,
mechanisms underlying both aging and cancer processes
are still subjects of controversies more than consensuses,
though cancer and aging seem to share common, rather
than antagonistic, etiologies [3]. Notwithstanding, it
ought to be emphasized that the onset of many chronic
illnesses, including cancer, is occurring today at an aver-
age age earlier than ever, with a progressive leftward
shift in the age of onset of various diseases including
diabetes, cancer and obesity [4, 5]. This alarming figure
would implies that, at least as far as cancer is concerned,
the increasing incidence of human malignancies is not
only related to the current increase in life expectancy,
but other key risk factors, mostly related to lifestyle and
environment, must be taken into account.
A number of both epidemiological and clinical stud-
ies strongly support the association between nutrition
and development or progression of major human can-
cers, including breast, prostate, and colorectal tumors,
but also many other tumor types have been recently
included in a hypothetical list of diet-related cancers
(reviewed in [6]).
There are many dietary components that have been
implicated as either protective or promoting factors
in cancer development. Several bioactive food compo-
nents, including polyphenols, selenium, methyl-group
donors, retinoids, mono- and poly-unsaturated fatty
acids, isothiocyanates and allyl compounds, have all
been claimed to have cancer prevention potential [7].
Although these compounds may impact upon a
variety of different cellular processes, such as DNA
repair, growth and differentiation, programmed cell
death, oxidative stress, inflammation and so forth, in
recent years the epigenome has been implicated as
the primary target for nutrition-induced changes of
gene expression and function [8].
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By definition, epigenetics comprises heritable changes
in gene expression with no alteration of DNA sequence
[9]. Major epigenetic mechanisms include DNA methy-
lation, histone modification and RNA interference
(RNAi) [10]. There is mounting evidence that all these
epigenetic processes can be implicated and act in syn-
ergy with genetic alterations during carcinogenesis and
tumor progression [11, 12]. However, contrary to genetic
mutations, epigenetic abnormalities are potentially re-
versible and can be targeted by both cancer prevention
and therapeutic strategies [13].
Convincing evidence is accumulating that many bio-
active dietary components may extensively modulate
epigenetic mechanisms, eventually leading to a rapid
and effective regulation of gene expression and function
in response to nutritional changes. In this respect, the
term epigenetic diet has been introduced to indicate the
consumption of foods, such as soy, grapes, cruciferous
vegetables and green tea, that affect epigenetic mecha-
nisms to protect against cancer and aging [14].
It is noteworthy that unbalanced maternal nutrient in-
take may severely impact on fetal epigenome early dur-
ing in utero development. There is increasing evidence
that nutritionally-induced epigenetic alteration of the
offspring’s epigenome may be responsible for higher sus-
ceptibility to cancer development later in life [15] and
that several epigenetic marks can be inherited and
reshape developmental and cellular features over genera-
tions, a phenomenon referred to as epigenetic inherit-
ance [16].
Mediterranean diet & disease risk: observational
and intervention studies
The term Mediterranean Diet was originally coined
after Angel Keys and his colleagues ascribed the sig-
nificantly lower rates of coronary heart disease ob-
served in Mediterranean countries, including Italy and
Greece, as compared to “northern” countries, such as
Netherlands, Finland and USA, to various factors and,
most notably, to the protective role of what they later
called the “good Mediterranean diet” and its typical
food components [17, 18].
Although there are various definitions of the Mediterra-
nean Diet (MD) in literature, it is difficult to describe in de-
tails a Mediterranean dietary pattern and its components.
According to Simopoulos [19], the term “Mediterranean
Diet” is in fact a misnomer, simply because there are many
different “Mediterranean diets”, based on cultural, ethnical,
religious and economical diversities among different popu-
lations and countries belonging to the Mediterranean basin.
However, the distinct Mediterranean Diets generally share
some major features, precisely: (a) a high consumption of
whole grains (over 60 % of total caloric intake), (b) a high
consumption of vegetables, fruits, and legumes; (c)
extravirgin olive oil for over 70 % of dietary fat; (d) a
regular consumption of fresh fish (especially marine
blue species); (e) a low intake of saturated animal
fats, red and processed meat, poultry, dairy products;
and (f ) with the exception of muslim populations, a
regular but moderate consume of red wine during
main meals.
Adherence to a Mediterranean dietary pattern has gen-
erally been associated with a decreased risk of dying for
most non-communicable diseases, including cardiovascu-
lar diseases, cancer, neurodegenerative diseases. Despite
the difficulty to assess the extent of adherence to this diet-
ary pattern and the limited number of studies exploring in
depth the impact of Mediterranean Diet on chronic dis-
eases and relevant pathogenetic mechanisms, both meta-
analyses and systematic reviews of the existing literature
have highlighted that Mediterranean Diet has a significant
protective role on risk of cardiovascular and neurodegen-
erative disease, diabetes and cancer [20–22].
As far as dietary interventions are concerned, the pro-
tective role of Mediterranean Diet against chronic dis-
eases has been challenged in a variety of studies.
The Lyon Diet Heart Study, a randomized secondary
prevention trial aimed at testing whether a Mediterra-
nean diet may reduce the rate of recurrence after a first
myocardial infarction, indicated that the adherence to a
Mediterranean dietary pattern has a significant protect-
ive role against secondary cardiac events, including
death and nonfatal myocardial infarction, and that this
effect is maintained up to 4 years after the first infarc-
tion, independent of major traditional risk factors, such
as high blood cholesterol and blood pressure [23].
After such a pioneering observation, a number of dietary
intervention studies have investigated the potential role of
Mediterranean diet in the prevention of cancer, obes-
ity, cardiovascular and neurodegenerative diseases.
Serra-Majem and Estruch [24], in a systematic review
of 35 experimental studies, indicated that Mediterra-
nean diet has favorable effects on lipoprotein levels,
endothelium vasodilatation, insulin resistance, metabolic
syndrome, antioxidant capacity, myocardial and cardiovas-
cular mortality, and cancer incidence in obese patients
and in those with previous myocardial infarction.
In a recent systematic review of 11 randomized
clinical trials for the Cochrane Collaboration, Rees
and colleagues [25] concluded that, despite the lim-
ited evidence available, Mediterranean diet positively
affects cardiovascular risk factors, including total
cholesterol and low-density lipoprotein (LDL) choles-
terol. More recently, Sleiman and associates [22]
systematically reviewed 24 studies (including cross-
sectional, prospective and controlled clinical trials) to
show that Mediterranean diet shows favorable effects
on both glycemic control and cardiovascular disease,
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while some degree of controversy remains on other
issues, such as obesity.
In the Moli-sani study, a large prospective cohort stud,
a Mediterranean-like diet was significantly associated
with lower values of glucose, lipids, CRP, blood pressure
and 10-year cardiovascular risk, while the consumption
of healthy foods with high content in antioxidant vita-
mins and phytochemicals correlated with lower blood
pressure and CRP plasma levels [26].
The PREDIMED study, a multicenter, randomized, pri-
mary prevention trial, showed that Mediterranean Diet,
supplemented with either extravirgin olive oil or nuts,
has favorable effect on blood pressure, insulin sensitivity,
lipid profiles, lipoprotein particles, inflammation, oxida-
tive stress, and carotid atherosclerosis [27].
As reviewed by Ostan and colleagues [28], there is
consisting evidence that nutrition modulates multiple in-
terconnected processes that play a major role in both
carcinogenesis and inflammatory responses, including
free radical production, NF-κB activation, expression of
inflammatory cytokines, and the eicosanoids pathway
[29]. In particular, Mediterranean Diet may positively
impact on the so called “inflammaging” through either
epigenetic mechanisms (that include chromatin remod-
eling, DNA methylation and miRNAs) or preservation of
gut microbiota homeostasis.
Primary prevention of breast cancer: The MeDiet
study
Breast cancer is the commonest malignancy in women
and the second most common neoplasm worldwide, ac-
counting for over 25 % of all female cancers [30]. It is
worth noting that breast cancer incidence and mortality
rates vary greatly across several countries, respectively
ranging from 25.6 to 95.3/100.000 and from 5.2 to 19.4/
100.000. This large variations may be ascribed to differ-
ences in both lifestyle and, notably, dietary habits among
different geographical areas. Results from migrant stud-
ies have indicated that breast cancer incidence dramatic-
ally changes in Asians migrating to USA and in their
offspring, with a steady increase from first to second and
third generation [31], suggesting that international varia-
tions in breast cancer incidence represent a consequence
of differences in lifestyle or environmental factors rather
than genetic differences.
Estrogens are primarily implicated in both develop-
ment and progression of human breast cancer, as either
genotoxic or promoting agents [32–34]. However, there
is little information on the impact that lifestyle, espe-
cially nutrition, produces on estrogen levels and metab-
olism and, hence on breast cancer risk.
Some years ago, we conducted the MeDiet study, a ran-
domized, dietary intervention trial aiming to determine
the effects of a traditional Mediterranean diet on endogen-
ous estrogens in healthy postmenopausal women [35].
Out of 230 healthy female volunteers, 115 women
were found to be eligible and were enrolled in the study
based on serum testosterone levels equal or greater than
0.14 mg/ml (median value), an arbitrary cut-off value
that has previously been reported to identify women at
higher risk of developing breast cancer [36, 37]. After
recruitment, study subjects were randomized into a diet-
ary intervention (n = 58) and a control (n = 57) group.
Women in the intervention group adopted a traditional,
controlled Mediterranean diet for 6 months, while
women in the control group continued to follow their
regular diet. The intervention group women were
instructed, through a weekly cooking course, to use and
cook food components of the traditional Sicilian
(Mediterranean) diet, including: whole cereals, legumes,
seeds, blue fish, extravirgin olive oil, vegetables, and
other Mediterranean seasonal food. Conversely, these
subjects were advocated to reduce and/or avoid use of
refined carbohydrates and additional animal fat, and to
limit the use of salt.
Before (baseline) and after dietary intervention, women
in both control and intervention groups undertook the
following: (a) compiled a food frequency questionnaire
originally developed for the EPIC study [38]; (b) collected
both fasting blood samples and 12 h urine samples; (c)
measured anthropometric indexes, including height,
weight, waist-to-hip ratio.
Urine samples were of special interest since our early
studies have indicated that metabolic profiles of urinary
estrogens could be used to discriminate breast cancer
patients in relation to their estrogen status, response to
hormone treatment and prognosis [39]. Furthermore,
urinary profiles of estrogens appear to be representative
of intratissue estrogen content, as defined in our previ-
ous studies [40].
Profiles of endogenous estrogens in urine of both
intervention and control women were assessed using a
high performance liquid chromatography (HPLC) sys-
tem, with both a photodiode array and an on line elec-
trochemical detection.
At baseline, no significant difference was observed in
urinary levels of individual estrogens comparing inter-
vention and control women. It is important to note that
the majority of urinary estrogens was represented by hy-
droxy and methoxy derivatives of both estradiol (E2)
and estriol (E3), rather than by parent estrogens (E2, E3,
and estrone – E1), in both control (75 %) and interven-
tion (84 %) groups. This finding is in accordance with
results of our early studies indicating that a high propor-
tion of estrogens in urines of breast cancer patients is
represented by hydroxylated metabolites of circulating
(mainly E2 and E1) estrogens, referred to as “minor” or
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“unusual” metabolites [39]. In addition, this picture is
cognate to what we have observed when measuring
intratissue profiles of estrogens in both normal and ma-
lignant human mammary gland, where hydroxy and/or
methoxy derivatives of either E2 or E1 represent the vast
majority of tissue estrogens while parent hormones
(E2, E1 and E3) account for a mere 5.2 % and 4.3 %
in nontumoral and malignant breast, respectively [40].
More importantly, some of these compounds, notably
hydroxylated metabolites and semiquinone or quinone
derivatives of either E2 or E1 have been implicated as
cancer-initiating or –promoting agents in breast car-
cinogenesis and tumor progression [32–34].
After 6 months, as expected, control women did not
show any major change, whilst women in the intervention
group showed a significant reduction (over 40 %, P < 0.02)
of total estrogen levels (Fig. 1). Interestingly, this modifica-
tion was in consequence of a remarkable reduction of es-
trogen metabolites, including hydroxy- and keto-
derivatives of E2 or E3, notably 2hydroxy-E2 (2OHE2),
17EpiE3 and 16KetoE2, whose concentrations decreased
by 80, 70 and 27 %, respectively (Fig. 2). At baseline, these
three compounds represented the majority of urinary es-
trogens in both control (57 %) and intervention (68 %)
women; after 6 months their levels dropped drastically in
the intervention group (54 %), while remained unchanged
in the control group (91 %). Conversely, E2, which repre-
sented a mere 0.2 % of total urinary estrogens, showed a
limited though statistically significant increase in the inter-
vention group (see Fig. 2), presumably because of its de-
creased biotransformation into 2OHE2 and 16KetoE2 that
occurs in the intervention group.
Overall, this MeDiet study has provided convincing
experimental evidence of two-fold value. In the first
place, it has further highlighted the fact that both hy-
droxy and methoxy estrogen derivatives account for the
vast majority of endogenous estrogens in human urine
and that urinary estrogen profiles can be considered
much closer to intratissue estrogen content than re-
spective plasma values, where only parent estrogens (E2,
E1, E3), that represent a limited fraction (5–8 %) of total
endogenous estrogens, could be measured. Secondly,
this study has clearly indicated that traditional Mediter-
ranean diet may reduce the risk of developing breast
cancer also through its effects on estrogen metabolism,
whereby hydroxylation of E2 at C2, C16α and C16β pos-
ition, a process eventually leading to the formation of
genotoxic metabolites, is remarkably decreased in the
intervention group but remains unchanged in the con-
trol group (Fig. 3).
Primary prevention of cancer and
noncommunicable diseases: the DiMeSa project
Today the crisis of the agrifood sector across several
geographical European areas, including our own, com-
bined with the recent economic crisis running at re-
gional, national and community level, is featured by
extremely critical aspects, mainly residing in the limited
innovation potential of companies and enterprises, the
lack of integration with public-private research institu-
tions, the insufficient systematization and organization
of the existing resources in an extended territorial net-
working. This criticism results into increasing difficulties
of small/medium enterprises (SMEs) to be present in
both domestic and foreign markets with characteristics
of quality and competitiveness.
On the other hand, several epidemiological studies
clearly indicate that all Western regions, including our
country, are facing a dramatic phenomenon consisting of
real epidemics of chronic diseases (cardiovascular,
cerebro-vascular, and respiratory diseases, diabetes, obes-
ity, metabolic syndrome) and tumors, whose causes are
largely attributable to (removable) lifestyle risk factors,
notably diet [41]. In particular, the gradual abandonment
Fig. 1 Levels of total urinary estrogens in both control and
intervention women at baseline and after 6 months in the MeDiet
study. Average values ± SDs are represented
Fig. 2 Changes of estrogen concentrations in intervention women after
6 months in the MeDiet study. Data represent % of control, as compared
with baseline values, ±SDs of estradiol (E2), 2hydroxy-estradiol (2OHE2),
17epi-estriol (17epiE3) and 16keto-estradiol (16ketoE2)
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of the traditional principles and food of Mediterra-
nean diet, that have protected for decades populations
of Southern Europe, including Italy, Greece and
Spain, is leading to a significant increase in incidence
rates of these diseases in our region, where today,
paradoxically, the highest European percentages of
obese and/or overweight adolescents are being ob-
served [42]. Since mortality from these diseases, that
we might rightfully define lifestyle-based, is steadily
declining since 90ies, thanks to more effective early
diagnosis and to advancements in treatment options,
we are witnessing an alarming “scissor” phenomenon,
where a progressive increase in the number of new
cases/year is accompanied by a significant reduction
number of deaths, with a remarkable and continuous
increase in the number of chronically ill individuals
(prevalence) [41]. This phenomenon, has an eco-
nomic, social and health impact of enormous import-
ance worldwide, to the point that the World Health
Organization (WHO), along with all major health institu-
tions, have proposed primary prevention as the only ef-
fective approach to halt and eventually reverse it and
launched a pluriannual (2013–2020) action plan for the
prevention and control of non-communicable diseases
based on a comprehensive intersectorial strategy targeting
the removal of primary risk factors for these diseases,
notably western diet [43]. Based on this combined consid-
eration, promoting both production and competitiveness
of traditional food products in regional, domestic and for-
eign markets through a series of activities aimed at in-
creasing their health and/or nutraceutical potential, to
clinically validate their effects on both health and chronic
disease(s), and to enable rapid technological transfer and
industrial development of either processes or products
would represent a systemic strategy of high impact in the
short, medium and long term for the important expected
outcome from an economic, technological and healthcare
standpoint.
Armed with this conception, in October 2012 we
embarked on a large regional project, funded by the Ital-
ian Ministry of University and Research (MIUR), leaded
by the The AgroBioPesca Technology Cluster, called
“DiMeSa - Valorization of typical products of Mediterra-
nean Diet and their use for health and nutraceutical pur-
poses”, where DiMeSa stands for Dieta MEditerranea e
Salute, simply Mediterranean Diet and Health.
This project was mainly aimed at multiplying the at-
tractiveness and market capacities of the traditional prod-
ucts of Mediterranean diet in regional agriculture through
the development and implementation of industrial re-
search and experimental development activities that
would eventually lead to improve their health potential
and that, at the same time, would validate scientifically the
relationship existing between selected Mediterranean food
products and health, both in terms of maintaining a well-
being state and, especially, of primary disease prevention.
The DiMeSa project is arranged into four major objec-
tives, precisely:
1. the analysis and identification of traditional food
processes and the development of innovative
biotechnological protocols for the production of
food with high nutritional and health potential,
including extra virgin olive oil, cereals or vegetables
and their derivatives;
2. the definition and implementation of procedures and
methodological approaches for the production of
functional foods (exra virgin olive oil, pasta, juices)
through their enrichment (functionalization) with
natural substances and/or plant/byproducts extracts
having high health potential and their distribution
through innovative vending machines;
3. the clinical validation of specific health claims
through the conduction of randomized, controlled
clinical trials to assess the health effects of selected
functional food products on cohorts of either
healthy, high-risk or diseased study-subjects through
the evaluation of the impact of dietary intervention
on some clinical and biomolecular end-points, such
as: a) anthropometric measures; b) immunological
A
B
Fig. 3 Extent of 16α and 16β hydroxylation in control (a) and
intervention (b) women of the MeDiet study. Data represent
average ± SD percent values of individual reaction at both baseline
and after 6 months
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markers of inflammation; c) oxidative stress and
endothelial function; d) hormonal profiles and gene
expression;
4. the economic evaluation of the concept, traceability
and industrial scale-up of either prototypal products
or processes aiming to allow their immediate
industrialization and successful marketing.
The project itself is a multicenter study, characterized
by a rather large partnership, that included regional
Universities and other public research institutions, on
one end, and small/medium enterprises (SMEs), on the
other (see Table 1). The project run for 39 months and
ended just recently, by December 2015.
In this framework, we have conducted a randomized
clinical trial for the assessment of the health impact of
extravirgin olive oil (EVO) on 2 cohorts of study subjects
represented by healthy postmenopausal women and pa-
tients with breast cancer. All study subjects were re-
cruited at the Azienda di Rilievo Nazionale e di Alta
Specializzazione (ARNAS) - Civico, Di Cristina, Benfra-
telli. Overall, 103 healthy postmenoausal women and 35
breast cancer patients were enrolled in the study. Two
different mono-cultivar EVOs, one at lower (BL) and
one at higher (CS) content of polyphenols and oleocan-
tal, were used in the study; both EVOs were produced
by the SAF (Scienze Agrarie e Forestali) Department of
Palermo University, under the supervision of Prof.
Tiziano Caruso. As regards healthy women, after an ini-
tial 1 week wash-out period (“no EVO” week), the sub-
jects consumed a daily amount of 30 ml of the BL EVO
for 4 weeks, followed by another 1 week wash-out
period (“no EVO”) and an additional 4 weeks interven-
tion with the CS EVO, as illustrated in Fig. 4.
Conversely, breast cancer patients were randomized into
one BL EVO and one CS EVO intervention group that
consumed daily amounts of 30 ml of either BL or CS
EVO for 4 weeks (see Fig. 4). Both healthy and breast
cancer study subjects, before and after any EVO inter-
vention, undertook the following: (a) compiled a food
frequency questionnaire originally developed for the
EPIC study [38]; (b) measured anthropometric indexes,
including height, weight, waist-to-hip ratio; (c) were ad-
ministered psychometric tests (HADS, SF-36); (d)
Table 1 The DiMeSa Project: partnerships
Public SMEs








• University of Catania
- Dip. Scienze del Farmaco
- D3Di
• University of Messina
- Dip. Clinico-Sperimentale
di Medicina e Farm.








- Oleificio San Calogero
- Az. Agr. Angela Consiglio
- Azienda “GeOlive” Belice
- Pastificio Tomasello SpA
- Laboratorio di Ricerche
Locorotondo
• Innova Agro Sicilia





Fig. 4 Flow chart of a randomized clinical trial in the DiMeSa project to assess the effects of extravirgin olive oil on selected parameters in both
healthy postmenopausal women and breast cancer patients. For explanation see text
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collected both fasting blood samples and 12 h urine
samples. These latter were collected to determine the
potential effect of dietary intervention on an array of both
plasmatic and serum biomarkers, the expression profiles
of a set of previously selected genes, the whole miRNome
and the urinary profile of sex steroid hormones.
Biological samples (plasma, serum, urine) were col-
lected and stored in a biobank that, as far as the EVO
clinical trial is concerned, included 5364 plasma/serum
aliquots and 756 urine aliquots. A web-based study data-
base was also created and data processed using advanced
statistical analysis.
Currently, only preliminary results of the trial are
available, concerning specifically a series of plasmatic
biomarkers, before and after dietary intervention, in
both healthy women and breast cancer patients. As re-
ported in Table 2, consumption of BL EVO resulted in
significant changes of various plasmatic biomarkers in
both healthy subjects and breast cancer patients. In par-
ticular, the reduction of glycemia, insulinemia and total
cholesterol levels appears of special interest. On the
other hand, the consumption of CS EVO produced sev-
eral modifications in selected biomarkers (see Table 3),
including a significant increase of HDL cholesterol and
reduction of LDL cholesterol. Interestingly, this EVO
also induced a marked decrease of plasmatic levels of es-
tradiol. It appears noteworthy that, when comparing the
two EVOs, BL EVO appeared to be more effective in
reducing glycemia, while CS EVO proved to be more ef-
fective in decreasing plasmatic estradiol (see Table 4).
This would imply that different EVOs may have a dis-
tinct impact on either glycemic control or hormonal
(sex steroid) status, also depending on the cultivar and
on the phenology of fruit ripening (the ealier the stage,
the greater the content of polyphenols).
Results of gene expression, microRNA profiling and
patterns of urinary sex steroids are currently under stat-
istical analysis and are awaited with great expectation
and interest.
Conclusions and perspectives
Doubtlessly, environment and lifestyle play a major role
in human health and aging. An amazing array of envir-
onmental factors and nutrition may have in fact a major
impact upon cellular and molecular processes, challen-
ging severely cell adaptation capacities and the mainten-
ance of tissue homeostasis. In this scenario, various
aspects related to diet may be of crucial importance,
including caloric intake, meal timing, balance of macro-
and micro-nutrients, microbiome regulation [44]. Re-
cently, WHO Europe launched a campaign for health
promotion through a life-course approach, with the
motto “Act Early, Act on Time, Act Together”. This ap-
proach encompasses virtually all key health issues and
relevant determinants throughout the entire life cycle,
including pre- and perinatal life, adulthood and aging, as
depicted in Fig. 5.
Data from our dietary intervention studies have
underlined some interesting aspects related to both
mechanisms underpinning biological and clinical ef-
fects of nutrition, on one hand, and specific activities
of Mediterranean food components, on the other. In
particular, the MeDiet study has provided evidence
that Mediterranean diet may regulate estrogen metab-
olism in postmenopausal women in a way that the
formation of potentially harmful genotoxic com-
pounds is remarkably reduced, while levels of parent
hormone estradiol are slightly increased; this would
imply that traditional Mediterranean food reduces the
risk of developing breast cancer while limiting the
side-effects of estrogen withdrawal in menopause.
Table 2 Effects of BL EVO on plasmatic biomarkers in both
healthy postmenopausal women and breast cancer patients
Variable Baseline After p-valuea
Azotemia 30.85 28.48 0.002
Uricemia 4.17 4.29 0.001
Glycemia 85.35 83.59 0.021
Insulinemia 10.33 8.79 <0.001
Total cholesterol 207.48 197.12 <0.001
Gamma GT 21.90 24.50 0.001
Total Proteinemia 7.00 6.91 0.005
Sideremia 76.95 67.02 <0.001
apaired T test, ANOVA
Table 3 Effects of CS EVO on plasmatic biomarkers in both
healthy postmenopausal women and breast cancer patients
Variable Baseline After p-valuea
Cretininemia 0.69 0.63 <0.001
Uricemia 4.23 4.43 0.002
Glycemia 89.16 88.48 0.023
Glycated hemoglobin 5.64 5.51 <0.001
HDL cholesterol 57.87 59.31 0.023
LDL cholesterol 119.62 102.12 0.047
Testosterone 0.39 0.36 0.033
Estradiol 31.40 23.95 0.002
apaired T test, ANOVA
Table 4 Comparison of the effects of BL and CS EVO on
glycemia and estradiol levels in both healthy postmenopausal
women and breast cancer patients
Variable BL EVO CS EVO p-valuea
Glycemia 83.59 88.48 0.023
Estradiol 37.21 23.95 0.027
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On the other hand, the DiMeSa project has indicated that
technological innovation and prototypical industrialization
of either processes or products could be used to obtain
traditional Mediterranean food having high health potential
and market capacities. Precisely, the production of mono-
cultivar extravirgin olive oils (EVOs) has revealed that se-
lected EVO(s) may have a differential activity on different
cellular and metabolic processes, eventually leading to pro-
duce highly characterized EVOs with a preferential use for
the prevention and care of distinct chronic diseases.
Nevertheless, further large, multicentric and long-term,
prospective intervention studies are yet necessary to dis-
sect the real effects of a strictly defined Mediterranean
dietary pattern on both individual risk of noncommunic-
able diseases and the underpinning action mechanisms.
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